Printer Friendly

ARBUTAMINE CLINICAL AND PRECLINICAL DATA ABSTRACTS PUBLISHED IN CIRCULATION

 ARBUTAMINE CLINICAL AND PRECLINICAL DATA
 ABSTRACTS PUBLISHED IN CIRCULATION
 SAN DIEGO, Oct. 19 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that data from Phase 2 clinical trials and one preclinical study with arbutamine (a drug which is part of the GenESA System) have been published in circulation and are scheduled to be presented by researchers from The Netherlands, UCLA Medical Center and the San Diego V.A. Medical Center at the 65th Scientific Sessions of the American Heart Association (AHA), Nov. 16-19, 1992.
 One AHA abstract reports on a European Phase 2 multicenter clinical trial, which was the first evaluation of the GenESA System in patients with coronary artery disease. The GenESA System consists of a computer-controlled, closed-loop delivery system in which the patient's heart rate response to arbutamine automatically determines the amount of drug administered, within protocol specifications. Data from 69 patients enrolled in this clinical trial indicated that arbutamine was a useful stress agent for the detection of coronary artery disease and myocardial ischemia (lack of oxygenated blood flow to the heart muscle) when used with electrocardiography (ECG) and echocardiography. In addition, closed-loop delivery of arbutamine appeared to be safe and well-tolerated in this study. ECG and echocardiography performed with exercise are the primary methods used for the diagnosis of coronary artery disease. An additional abstract describes results from a U.S. multicenter Phase 2 clinical trial with arbutamine. In this trial, arbutamine was administered intravenously by a physician. Data from 16 patients studied at UCLA Medical Center indicated that the quantitative echocardiographic signs of myocardial ischemia evoked by arbutamine appeared to be similar to those produced by exercise.
 The third abstract describes a preclinical study performed at the V.A. Medical Center in San Diego which found that arbutamine appeared to be more effective than dobutamine in its ability to produce diagnostic signs of coronary artery disease when measured with an ultrasound technique similar to clinical echocardiography, even though the drugs are structurally similar catecholamine compounds. Although not approved by the Food and Drug Administration for pharmacological stress testing in the United States, dobutamine is currently used with echocardiography by some clinicians to diagnose coronary artery disease.
 "These clinical studies provide additional support for the safety and efficacy of arbutamine and the GenESA System for use in the diagnosis of coronary artery disease," said David F. Hale, chairman, president and chief executive officer. "In addition, the preclinical research comparing arbutamine to dobutamine reflects what potentially may be an important difference between the two drugs when used with echocardiography."
 In order to diagnose coronary artery disease, in most patients it is usually necessary to stress the heart, typically with physical exercise. If blockages exist in the coronary arteries, they will prevent the required flow of blood during stress, resulting in ischemia and cardiac dysfunction. Depending on the severity of the dysfunction, it can usually be detected by electrocardiography (ECG), echocardiography or radionuclide imaging.
 The GenESA System combines arbutamine and a computer-controlled drug administration system designed to pharmacologically stress the heart to aid in the diagnosis of coronary artery disease. The GenESA System is currently being tested in multicenter Phase 3 clinical trials with three commonly used diagnostic techniques: ECG, echocardiography and radionuclide imaging. Gensia expects to complete enrollment in the Phase 3 clinical trials with the GenESA System by the end of 1992, and assuming positive results in these trials, to make regulatory submissions in the United States, Canada and Western Europe in mid-1993, according to Hale.
 The company believes that a primary clinical need for the GenESA System is for use with patients who are unable to undergo exercise stress tests or who have had inconclusive exercise stress ECG tests. In addition, the GenESA System is also expected to enhance echocardiography, which is a rapidly growing cardiac test worldwide, and radionuclide imaging procedures which are difficult to perform in conjunction with physical exercise.
 The company estimates that in the United States, as many as 1.5 million patients who are candidates for testing for coronary artery disease are unable to exercise adequately because of physical disabilities or limitations. In addition, of the 6 million exercise stress ECGs performed each year in the United States, an estimated 20 percent to 30 percent of tests are inconclusive, frequently because the patient is unable to achieve a sufficient increase in heart rate for diagnosis of coronary artery disease to be made. There are approximately 6 million echocardiography and 1.5 million radionuclide imaging procedures performed each year in the United States.
 Gensia Clinical Partners owns certain rights to the GenESA System technology which are subject to a purchase option by Gensia.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnoses of human diseases.
 -0- 10/19/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU:


LS-KJ -- SD008 -- 1385 10/19/92 09:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1992
Words:833
Previous Article:15TH ANNUAL COMMUNICATIONS MANAGERS ASSOCIATION CONFERENCE AND EXPOSITION SET FOR OCT. 19-22 IN NEW YORK
Next Article:CHART HOUSE REPORTS THIRD QUARTER RESULTS
Topics:


Related Articles
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
ARBUTAMINE PHASE 2 CLINICAL DATA ABSTRACT PUBLISHED IN JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
DATA ON ARBUTAMINE PRESENTED AT ACC
ARBUTAMINE PHASE 3 CLINICAL ABSTRACTS PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
SCIOS NOVA ANNOUNCES THAT BASIC FIBROBLAST GROWTH FACTOR DECREASES BRAIN INJURY IN A PRECLINICAL ANIMAL MODEL OF STROKE
AltaRex Publishes Early Prospective OvaRex(TM) MAb Data in the Journal Blood And Announces Updated Results.
Aronex Pharmaceuticals Reports Pivotal Clinical and Preclinical Data On ATRAGEN(R) in Patients With Acute Promyelocytic Leukemia.
NeoPharm and collaborators unveil cancer study results.
INEX Selects Vinorelbine TCS as the Third Drug for Development from its Targeted Chemotherapy Product Pipeline.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters